Genomic Testing Cooperative’s Post

GTC published an abstract at ASCO titled Multiple Alternative Splicing of HER2 transcripts and Exon Skipping with Potential Consequences on Function and Antibody-Based Therapy. Check out this abstract: https://lnkd.in/eEdFuHeV #Exonskipping #Alternativesplicing #RNA #ASCO

looking forward this webinar! #tgrd #hcc #girisimselradyoloji #interventionalradiology #hepatocellularcarcinoma #immunotherapy #tace #chemoembolization #kemoembolizasyon #embolization

Updated in MGS! Read the chapter on "Metoprolol Therapy and CYP2D6 Genotype" that includes guidelines from #CPICpgx: https://ow.ly/QvGq50TIbqj

🏆 Insilico Medicine reports positive Phase IIa results for ISM001-055, a novel first-in-class drug treatment for idiopathic pulmonary fibrosis (IPF) designed using generative AI For the full release, please visit: https://lnkd.in/g4Hjazr2 #GenAIPhase2 #Phase2AI 

Come learn about the role of CAR-T therapy in hematologic malignancies. We will also discuss the mechanism action of CAR-T therapy and patient considerations. Go to https://bit.ly/3uGWqDt. #CRANE

Understanding the difference between BENEV Exosomes and PRP: PRP: Platelet-Rich Plasma (PRP) is derived from patients' own blood, is made up of plasma and platelet cells and triggers the body’s inflammatory response. BENEV Exosomes: BENEV Exosomes, on the other hand, are naturally anti-inflammatory, derived from human adipose tissue, and are not cells. Double tap if you love using BENEV Exosomes! #exosomeregenerativecomplex #exosometechnology #exosometreatment *Disclaimer: BENEV Exosome Regenerative Complexes are not drug products. They are not intended to prevent, treat, or cure diseases or medical conditions. They are not intended to be injected or delivered intravenously.

💡A: Starting material is the foundation of #cellulartherapy. High-quality starting material ensures the safety, efficacy, and consistency of the final therapeutic product. It directly impacts the success of the therapy by influencing cell growth, differentiation, and function. In essence, it sets the stage for the entire therapeutic process, making it a critical element in achieving successful patient outcomes. #BloodCancers #Cryopreservation #CellProcessing

Tenapanor (a novel phosphate absorption inhibitor that blocks the sodium/hydrogen exchanger 3) is a promising therapy for hyperphosphatemia in maintenance dialysis patients, as per the latest results from the OPTIMIZE study. The study found that Tenapanor as monotherapy or in combination with PBs effectively lowered P towards the target range, even in patients who were PB naive or not at goal despite PB use. These findings are a positive step forward in managing hyperphosphatemia in patients with CKD. Read more about this study here: DOI: 10.34067/KID.0000000000000387 #Tenapanor #Hyperphosphatemia #CKD #OPTIMIZEStudy

𝗗𝗶𝗱 𝘆𝗼𝘂 𝗸𝗻𝗼𝘄 𝗶𝘁'𝘀 𝗽𝗼𝘀𝘀𝗶𝗯𝗹𝗲 𝘁𝗼 𝗰𝗼𝗺𝗯𝗶𝗻𝗲 𝘀𝗲𝘃𝗲𝗿𝗮𝗹 𝗠𝗖𝗧 𝗣𝗿𝗲𝘀𝗲𝘁𝘀? By combining PRP or Cells presets with the Exosomes preset, we can achieve even more potent therapeutic outcomes. Here’s how it works: 𝟭. 𝗦𝗽𝗹𝗶𝘁𝘁𝗶𝗻𝗴 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗠𝗮𝘁𝗲𝗿𝗶𝗮𝗹: The patient’s material is divided into two equal halves. 𝟮. 𝗙𝗶𝗿𝘀𝘁 𝗵𝗮𝗹𝗳: Used for PRP or Cells presets to obtain either MCT Plasma or MCT Cells. 𝟯. 𝗦𝗲𝗰𝗼𝗻𝗱 𝗵𝗮𝗹𝗳: Used to run the Exosomes preset, generating MCT Exosomes. This approach allows patients to benefit from both MCT Plasma or MCT Cells and MCT Exosomes, providing an enhanced treatment experience. #MCT #PRP #Exosomes #Cells #MCTCombinedTreatment

Production and characterization of no-carrier-added 161Tb as an alternative to the clinically-applied 177Lu for radionuclide therapy